# Birchview Capital, LP 13F holdings Q2 2026: $214 million

Birchview Capital, LP reported $214 million in 13F securities across 72 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Kla Corp at $53.8 million, 25.2% of the reported value. Since Q1 2026 it opened 14 new positions and exited 15.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $213,828,198
- Positions: 72
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1618205
- Form 13F file number: 028-16416
- Business address: 688 Pine Street, Suite D C/O Birchview Capital, Burlington, VT 05401
- SEC filing: [0001618205-26-000003](https://www.sec.gov/Archives/edgar/data/1618205/000161820526000003/0001618205-26-000003-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/birchview-capital-lp-170534)

## Top 25 holdings by value

The largest of 72 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Kla Corp](https://specstream.ai/data/institutional-holders/kla-corp-482480100) | COM NEW | 178,471 | $53.8 million | +158,588 |
| [Bristol-Myers Squibb Co](https://specstream.ai/data/institutional-holders/bristol-myers-squibb-co-110122108) | COM | 297,243 | $17.1 million | -9,025 |
| [Lam Research Corp](https://specstream.ai/data/institutional-holders/lam-research-corp-512807306) | COM NEW | 35,000 | $15.2 million | -1,000 |
| [Intellia Therapeutics Inc](https://specstream.ai/data/institutional-holders/intellia-therapeutics-inc-45826j105) | COM | 385,900 | $6.8 million | -59,500 |
| [Solid Biosciences Inc](https://specstream.ai/data/institutional-holders/solid-biosciences-inc-83422e204) | COM NEW | 666,196 | $6.7 million | +40,216 |
| Biodesix Inc | COM | 286,804 | $6.5 million | No change |
| [Stoke Therapeutics Inc](https://specstream.ai/data/institutional-holders/stoke-therapeutics-inc-86150r107) | COM | 178,110 | $5.8 million | -31,890 |
| [Ovintiv Inc](https://specstream.ai/data/institutional-holders/ovintiv-inc-69047q102) | COM | 107,500 | $5.7 million | No change |
| [Nektar Therapeutics](https://specstream.ai/data/institutional-holders/nektar-therapeutics-640268306) | COM NEW | 81,000 | $5.7 million | +50,000 |
| [Corcept Therapeutics Inc](https://specstream.ai/data/institutional-holders/corcept-therapeutics-inc-218352102) | COM | 57,200 | $5 million | +10,000 |
| [Neurocrine Biosciences Inc](https://specstream.ai/data/institutional-holders/neurocrine-biosciences-inc-64125c109) | COM | 27,190 | $4.6 million | No change |
| [Prothena Corp PLC](https://specstream.ai/data/institutional-holders/prothena-corp-plc-g72800108) | SHS | 449,019 | $4.4 million | No change |
| [Acadia Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/acadia-pharmaceuticals-inc-004225108) | COM | 171,000 | $4.3 million | No change |
| [Protagonist Therapeutics Inc](https://specstream.ai/data/institutional-holders/protagonist-therapeutics-inc-74366e102) | COM | 35,018 | $4.3 million | +18 |
| [Compass Therapeutics Inc](https://specstream.ai/data/institutional-holders/compass-therapeutics-inc-20454b104) | COM | 1,675,000 | $3.7 million | +209,133 |
| [Relmada Therapeutics Inc](https://specstream.ai/data/institutional-holders/relmada-therapeutics-inc-75955j402) | COM | 408,100 | $2.8 million | -1,287 |
| [Alkermes PLC](https://specstream.ai/data/institutional-holders/alkermes-plc-g01767105) | SHS | 50,000 | $2.6 million | No change |
| [Halozyme Therapeutics Inc](https://specstream.ai/data/institutional-holders/halozyme-therapeutics-inc-40637h109) | COM | 33,251 | $2.6 million | +23,151 |
| [Celldex Therapeutics Inc New](https://specstream.ai/data/institutional-holders/celldex-therapeutics-inc-new-15117b202) | COM NEW | 69,900 | $2.6 million | -195 |
| [Cytokinetics Inc](https://specstream.ai/data/institutional-holders/cytokinetics-inc-23282w605) | COM NEW | 30,000 | $2.6 million | No change |
| [Olema Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/olema-pharmaceuticals-inc-68062p106) | COM | 199,000 | $2.5 million | -20,000 |
| [Vera Therapeutics Inc](https://specstream.ai/data/institutional-holders/vera-therapeutics-inc-92337r101) | CL A | 57,758 | $2.5 million | +13,758 |
| [United Therapeutics Corp Del](https://specstream.ai/data/institutional-holders/united-therapeutics-corp-del-91307c102) | COM | 4,506 | $2.4 million | +6 |
| [Zenas Biopharma Inc](https://specstream.ai/data/institutional-holders/zenas-biopharma-inc-98937l105) | COM | 93,601 | $2.4 million | +23,601 |
| [Uniqure NV](https://specstream.ai/data/institutional-holders/uniqure-nv-n90064101) | SHS | 50,697 | $2.3 million | -50,000 |

## New positions in Q2 2026

14 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Abivax SA](https://specstream.ai/data/institutional-holders/abivax-sa-00370m103) | SPONSORED ADS | 17,000 | $2.3 million |
| [Vir Biotechnology Inc](https://specstream.ai/data/institutional-holders/vir-biotechnology-inc-92764n102) | COM | 220,000 | $2.2 million |
| [Bioage Labs Inc](https://specstream.ai/data/institutional-holders/bioage-labs-inc-09077v100) | COM | 69,000 | $1.7 million |
| [Novo-Nordisk a S](https://specstream.ai/data/institutional-holders/novo-nordisk-a-s-670100205) | ADR | 24,000 | $1.2 million |
| [Adagene Inc](https://specstream.ai/data/institutional-holders/adagene-inc-005329107) | ADS | 240,000 | $1 million |
| [Definium Therapeutics Inc](https://specstream.ai/data/institutional-holders/definium-therapeutics-inc-24477v105) | COM SHS | 20,000 | $940,800 |
| [Silence Therapeutics PLC](https://specstream.ai/data/institutional-holders/silence-therapeutics-plc-82686q101) | ADS | 71,218 | $781,974 |
| [4d Molecular Therapeutics in](https://specstream.ai/data/institutional-holders/4d-molecular-therapeutics-in-35104e100) | COM | 48,505 | $645,117 |
| [Urogen Pharma LTD](https://specstream.ai/data/institutional-holders/urogen-pharma-ltd-m96088105) | COM | 16,487 | $606,722 |
| [Camp4 Therapeutics Corp](https://specstream.ai/data/institutional-holders/camp4-therapeutics-corp-13463j101) | COM | 120,000 | $524,400 |
| [Savara Inc](https://specstream.ai/data/institutional-holders/savara-inc-805111101) | COM | 80,000 | $492,800 |
| [Altimmune Inc](https://specstream.ai/data/institutional-holders/altimmune-inc-02155h200) | COM NEW | 152,681 | $464,150 |
| [Capricor Therapeutics Inc](https://specstream.ai/data/institutional-holders/capricor-therapeutics-inc-14070b309) | COM NEW | 14,352 | $345,596 |
| [Invivyd Inc](https://specstream.ai/data/institutional-holders/invivyd-inc-00534a102) | COM | 342,275 | $298,601 |

## Positions exited in Q2 2026

15 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Novocure LTD](https://specstream.ai/data/institutional-holders/novocure-ltd-g6674u108) | ORD SHS | 202,330 | $2.2 million |
| Engene Holdings Inc | COM | 250,000 | $1.7 million |
| [Ultragenyx Pharmaceutical in](https://specstream.ai/data/institutional-holders/ultragenyx-pharmaceutical-in-90400d108) | COM | 62,000 | $1.3 million |
| Kalvista Pharmaceuticals Inc | COM | 57,000 | $1.1 million |
| [Verastem Inc](https://specstream.ai/data/institutional-holders/verastem-inc-92337c203) | COM NEW | 150,000 | $795,000 |
| [Apogee Therapeutics Inc](https://specstream.ai/data/institutional-holders/apogee-therapeutics-inc-03770n101) | COM | 9,000 | $757,530 |
| Apellis Pharmaceuticals Inc | COM | 14,000 | $563,220 |
| [Ideaya Biosciences Inc](https://specstream.ai/data/institutional-holders/ideaya-biosciences-inc-45166a102) | COM | 16,860 | $561,775 |
| [Arcus Biosciences Inc](https://specstream.ai/data/institutional-holders/arcus-biosciences-inc-03969f109) | COM | 25,889 | $559,202 |
| [Regenxbio Inc](https://specstream.ai/data/institutional-holders/regenxbio-inc-75901b107) | COM | 66,270 | $555,343 |
| [Rocket Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/rocket-pharmaceuticals-inc-77313f106) | COM | 127,025 | $454,750 |
| [Viridian Therapeutics Inc](https://specstream.ai/data/institutional-holders/viridian-therapeutics-inc-92790c104) | COM | 20,100 | $393,156 |
| Outset Medical Inc | COM | 98,882 | $379,707 |
| [Phreesia Inc](https://specstream.ai/data/institutional-holders/phreesia-inc-71944f106) | COM | 14,300 | $119,834 |
| [Zentalis Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/zentalis-pharmaceuticals-inc-98943l107) | COM | 17,503 | $40,957 |

## Also on SpecStream

- [Birchview Capital, LP Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1618205/000161820526000003/0001618205-26-000003-index.htm)
- [Birchview Capital, LP investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/birchview-capital-lp-170534)
- [Largest 13F filers in Vermont](https://specstream.ai/data/institutional-holdings/state/vermont)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in and around Burlington, Vermont

- [Law firms in Burlington, Vermont](https://specstream.ai/data/businesses/law-firms/burlington-vermont-united-states)
- [Colleges and universities in Burlington, Vermont](https://specstream.ai/data/businesses/colleges-and-universities/burlington-vermont-united-states)
- [Real estate firms in Burlington, Vermont](https://specstream.ai/data/businesses/real-estate-firms/burlington-vermont-united-states)
- [Legal services firms in Burlington, Vermont](https://specstream.ai/data/businesses/legal-services-firms/burlington-vermont-united-states)
- [IT service companies in Vermont, United States](https://specstream.ai/data/businesses/it-service-companies/vermont-united-states)
- [Personal injury law firms in Vermont, United States](https://specstream.ai/data/businesses/personal-injury-law-firms/vermont-united-states)
